The DOI matches its Crossref record, with a small difference in title or year; 34 of the 35 references it cites were found in a registry or an index.
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Open accessAbstract
BACKGROUND: Recent randomized clinical trials have suggested that estrogen plus progestin does not confer cardiac protection and may increase the risk of coronary heart disease (CHD). In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI). METHODS: The WHI included a randomized primary-prevention trial of estrogen plus progestin in 16,608 postmenopausal women who were 50 to 79 years of age at base line. Participants were randomly assigned to receive conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The primary efficacy outcome of the trial was CHD (nonfatal myocardial infarction or death due to CHD). RESULTS: After a mean follow-up of 5.2 years (planned duration, 8.5 years), the data and safety monitoring board recommended terminating the estrogen-plus-progestin trial because the overall risks exceeded the benefits. Combined hormone therapy was associated with a hazard ratio for CHD of 1.24 (nominal 95 percent confidence interval, 1.00 to 1.54; 95 percent confidence interval after adjustment for sequential monitoring, 0.97 to 1.60). The elevation in risk was most apparent at one year (hazard ratio, 1.81 [95 percent confidence interval, 1.09 to 3.01]). Although higher base-line levels of low-density lipoprotein cholesterol were associated with an excess risk of CHD among women who received hormone therapy, higher base-line levels of C-reactive protein, other biomarkers, and other clinical characteristics did not significantly modify the treatment-related risk of CHD. CONCLUSIONS: Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use. This treatment should not be prescribed for the prevention of cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CVD prevention in women.318”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [318]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [371]
Experimental — accuracy not yet measuredIn the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [371]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [371]
In the citing paper
“Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes [369-371].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [371]
In the citing paper
“Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CV prevention in women.166”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [166]
In the citing paper
“Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CVD prevention in women. 318”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [318]
In the citing paper
“and the higher palatability and acceptance of MeDiets in comparison with low-fat diets 17,18 lend support to our hypothesis.”
From Cohort Profile: Design and methods of the PREDIMED study (2012) · cites this paper as [18]
In the citing paper
“however, hormone replacement therapy does not consistently restore BP, suggesting additional regulatory mechanisms [ 177 ].”
From Sex differences in potassium regulation: evidence, molecular mechanisms and clinical implications (2026) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,119
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D. M., Ettinger, B. B., Ernster, V. L., & Cummings, S. R. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-12-1016 · Cited by 2,329
Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
Grady, D. G., Herrington, D. M., Bittner, V., Blumenthal, R. S., Davidson, M., Hlatky, M. A., Hsia, J. A., Hulley, S. B., Herd, A. J., Khan, S. S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,921
Self-citationEffect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington, D. M., Reboussin, D. M., Brosnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., Furberg, C. D., Kowalchuk, G. J., Stuckey, T. D., Rogers, W. J., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008243430801 · Cited by 1,242
Cited by
Sorted by citations
Items 801–900 of 1,001
Kulpa, J., Chinnappareddy, N., & Pyle, W. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041076 · Cited by 24
A systematic review of menopausal symptom management decision aid trials
Carpenter, J. S., Studts, J. L., & Byrne, M. M. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.02.005 · Cited by 24
Naves‐Díaz, M., Carrillo‐López, N., Rodríguez-Rodríguez, A., Braga, S., Fernández‐Coto, T., López-Novoa, J. M., López-Hernández, F. J., & Cannata-Andía, J. B. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181ce6874 · Cited by 24
Pharmacoeconomics and Pharmacoepidemiology
Briggs, A. H., & Levy, A. R. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624110-00005 · Cited by 24
Design of Observational Studies
Johnson, L. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-849905-4.00017-4 · Cited by 24
Effect of Gua sha therapy on perimenopausal syndrome: a randomized controlled trial
Meng, F., Duan, P., Zhu, J., Lou, Q.-Q., Fang, Z.-H., An, H.-L., Liu, L.-Y., Hu, Y. H., & Hu, Q. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000752 · Cited by 24
Ovarian Lipid Metabolism Modulates Circulating Lipids in Premenopausal Women
Jensen, J. T., Addis, I. B., Hennebold, J. D., & Bogan, R. L. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3456 · Cited by 24
Psychosocial work environment and lifestyle as related to lipid profiles in perimenopausal women
Evolahti, A., Hultcrantz, M. L., & Collins, A. (2008) · Climacteric · doi:10.1080/13697130802521290 · Cited by 24
Coronary heart disease and hormone replacement therapy after the menopause
Hodis, H. N., & Mack, W. J. (2009) · Climacteric · doi:10.1080/13697130903095178 · Cited by 24
Authors' Response, Part I: Observational Studies Analyzed Like Randomized Experiments
Hernán, M. Á., & Robins, J. M. (2008) · Epidemiology · doi:10.1097/ede.0b013e318188e85f · Cited by 24
Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis
Sanad, Z. F., Ellakwa, H., & Desouky, B. (2011) · Climacteric · doi:10.3109/13697137.2010.537408 · Cited by 24
Kornacewicz-Jach, Z., Kossuth, I., & Czechowska, M. (2006) · Menopause Review/Przegląd Menopauzalny · Cited by 24
Discoordinate regulation of renal nitric oxide synthase isoforms in ovariectomized mRen2.Lewis rats
Yamaleyeva, L. M., Gallagher, P. E., Vinsant, S. L., & Chappell, M. C. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00389.2006 · Cited by 24
Ajayi, A. A. L., Ogungbade, G. O., & Okorodudu, A. O. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01339.x · Cited by 24
Stampfer, M. J. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh191 · Cited by 24
Treatment validity for intervention studies.
Chambless, D. L., & Hollon, S. D. (2012) · APA handbook of research methods in psychology, Vol 2: Research designs: Quantitative, qualitative, neuropsychological, and biological. · doi:10.1037/13620-028 · Cited by 24
Desideratum for Evidence Based Epidemiology
Overhage, J. M., Ryan, P. B., Schuemie, M. J., & Stang, P. (2013) · Drug Safety · doi:10.1007/s40264-013-0102-2 · Cited by 23
Appropriate models for novel osteoporosis drug discovery and future perspectives
Gennari, L., Rotatori, S., Bianciardi, S., Gonnelli, S., Nuti, R., & Merlotti, D. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1080685 · Cited by 23
Tuomikoski, P., Haapalahti, P., Sarna, S. J., Ylikorkala, O., & Mikkola, T. S. (2010) · Annals of Medicine · doi:10.3109/07853891003796760 · Cited by 23
Estrogen in Cardiovascular Disease during Systemic Lupus Erythematosus
Gilbert, E., & Ryan, M. J. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.07.021 · Cited by 23
Endothelial biology in the post-menopausal obese woman
Meadows, J. L., & Vaughan, D. E. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.03.012 · Cited by 23
Vehmanen, L., Saarto, T., BLOMQVIST, C. P., Taskinen, M., & Elomaa, I. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601979 · Cited by 23
de Oliveira, T. S., de Oliveira, L. M., de Oliveira, L. P., da Costa, R. M., Tostes, R. C., Georg, R. D. C., Costa, É. A., Lobato, N. D. S., Filgueira, F. P., & Ghedini, P. C. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.07.003 · Cited by 24
Abiramasundari, G., Gowda, C. M. M., & SREEPRIYA, M. (2018) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2017.04.003 · Cited by 23
Hamidi, O., & Davidge-Pitts, C. J. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.02.001 · Cited by 23
Feldman, R. D. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.03.002 · Cited by 23
Gonnelli, S. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s3466 · Cited by 23
Leung, S. W. S., Teoh, H., Keung, W., & Man, R. Y. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04686.x · Cited by 23
A Review of Transdermal Nonpatch Estrogen Therapy for the Management of Menopausal Symptoms
Carroll, N. (2010) · Journal of Women s Health · doi:10.1089/jwh.2008.1206 · Cited by 23
Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland
Gallo, D., Zannoni, G. F., Martinelli, E., Ferlini, C., Fabrizi, M. M., Riva, A., Morazzoni, P., Bombardelli, E., & Scambia, G. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000191208.05491.94 · Cited by 23
Stevenson, J. C. (2004) · Current Osteoporosis Reports · doi:10.1007/s11914-004-0009-z · Cited by 23
Stradling, J. R. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2310012 · Cited by 23
Roehm, E. (2015) · Obstetrics and Gynecology International · doi:10.1155/2015/713295 · Cited by 22
Zhuang, Q., Chen, S., Zhang, W., Gu, M., Xiao, L., Li, Y., Yang, Y., Feng, C., Li, H., Geng, D., et al. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c05954 · Cited by 22
Complementary and alternative medicine in the treatment of menopausal symptoms
Shou, C., Li, J., & Liu, Z. (2011) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-011-0932-7 · Cited by 22
Aromatase inhibitors as adjuvant treatment of breast cancer
Geisler, J., & Lønning, P. E. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.05.005 · Cited by 23
Ovarian hormones and vascular disease
Hage, F. G., & Oparil, S. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32836205e7 · Cited by 22
Estrogen Receptor Polymorphisms and the Vascular Effects of Hormone Therapy
Rossouw, J. E., Bray, P. F., Liu, J., Kooperberg, C. L., Hsia, J. A., Lewis, C. E., Cushman, M., Bonds, D. E., Hendrix, S. L., Papanicolaou, G., et al. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.215087 · Cited by 22
Self-citationYang, S., & Prentice, R. L. (2015) · Statistics in Medicine · doi:10.1002/sim.6453 · Cited by 22
Lee, Y., Lim, W., & Sung, M. (2018) · Nutrients · doi:10.3390/nu10121984 · Cited by 23
Association of Migraine With Incident Hypertension After Menopause
MacDonald, C., Fatouhi, D. E., Madika, A., Fagherazzi, G., Kurth, T., Severi, G., & Boutron‐Ruault, M. (2021) · Neurology · doi:10.1212/wnl.0000000000011986 · Cited by 22
Warren, M. P., & Chua, A. L. (2006) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2006.04.003 · Cited by 22
Postmenopausal hormone therapy: Who now takes it and do they differ from non‐users?
Taylor, A. W., MacLennan, A. H., & Avery, J. (2006) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2006.00542.x · Cited by 22
Liew, R. (2003) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.10.006 · Cited by 22
Estrogen with and without progestin: benefits and risks of short-term use
LaCroix, A. Z. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.039 · Cited by 22
Management of metabolic syndrome: aspirin
Shields, T. M., & Hennekens, C. H. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.03.015 · Cited by 22
Where Are We Now with Hormone Replacement Therapy?
McPherson, K. (2004) · Reproductive Health Matters · doi:10.1016/s0968-8080(04)24144-1 · Cited by 22
Genazzani, A. R., & Simoncini, T. (2007) · Gynecological Endocrinology · doi:10.1080/09513590601179766 · Cited by 22
The healthy user effect in pharmacoepidemiology
Olawore, O., Stürmer, T., Glynn, R. J., & Lund, J. L. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae358 · Cited by 21
Servadei, F., Anemona, L., Cardellini, M., Scimeca, M., Montanaro, M., Rovella, V., Daniele, F. D., Giacobbi, E., Legramante, I. M., Noce, A., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01277-8 · Cited by 21
Knowledge and personal use of menopausal hormone therapy among Chinese obstetrician-gynecologists
Wang, Y., Yang, X., Li, X., He, X., & Zhao, Y. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000233 · Cited by 21
Observational Studies in a Learning Health System
Institute of Medicine (2013) · National Academies Press eBooks · doi:10.17226/18438 · Cited by 21
Progestogen safety and tolerance in hormonal replacement therapy
Palacios, S., & Mejía, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1223041 · Cited by 21
Heinemann, K., Rübig, A., Strothmann, A., Nahum, G. G., & Heinemann, L. A. J. (2008) · Journal of Women s Health · doi:10.1089/jwh.2007.0584 · Cited by 21
The role of estrogen receptor subtypes for vascular maintenance
Luksha, L., & Kublickiene, K. R. (2009) · Gynecological Endocrinology · doi:10.1080/09513590802485038 · Cited by 21
Foidart, J.-M., & Faustmann, T. A. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701582323 · Cited by 21
Hormonal Therapy: Does It Increase or Decrease Cardiovascular Risk?
Schnatz, P. F. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000238674.98471.bb · Cited by 21
Stampfer, M. J. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh125 · Cited by 21
Keech, C. A., Sashegyi, A. I., & Barrett-Connor, E. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079904x18045 · Cited by 21
Lukes, A. S. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s3-a.7 · Cited by 21
Postmenopausal hormone therapy and coronary heart disease in early postmenopausal women
Tuomikoski, P., & Mikkola, T. S. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.854982 · Cited by 22
Sex differences in sympathetic vasoconstrictor responsiveness and sympatholysis
Just, T. P., & DeLorey, D. S. (2017) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00139.2017 · Cited by 21
Advances in the management of hyperlipidemia-induced atherosclerosis
Tannock, L. R. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.369 · Cited by 21
Hunter, M. S. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543579.200 · Cited by 21
Hormone replacement therapy and cardiovascular disease revisited
Stevenson, J. C. (2009) · Menopause international · doi:10.1258/mi.2009.009018 · Cited by 21
Menopausal hormone therapy and coronary heart disease: the roller-coaster history
Nudy, M. S., Buerger, J. D., Dreibelbis, S., Jiang, X., Hodis, H. N., & Schnatz, P. F. (2023) · Climacteric · doi:10.1080/13697137.2023.2282690 · Cited by 20
do Nascimento, G. R. A., Barros, Y., Wells, A. K., & Khalil, R. A. (2009) · Current Hypertension Reviews · doi:10.2174/157340209789587717 · Cited by 20
Montalescot, G., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Sechtem, U. P., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.11.007 · Cited by 21
Preventive cardiology and cardiac rehabilitation programmes in women
Lloyd, G. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.02.002 · Cited by 20
Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy
Darabi, M., Rabbani, M., Ani, M., Zarean, E., Panjehpour, M., & Movahedian, A. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.507826 · Cited by 20
Wu, G., Lee, J.-J., Chou, D., Jayakumar, T., Hsiao, G., Chen, W., & Sheu, J. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.055 · Cited by 20
Al‐Nakkash, L., Martin, J., Petty, D., Lynch, S. M., Hamrick, C., Lucy, D., Robinson, J., Peterson, A., Rubin, L. J., & Broderick, T. L. (2012) · Gender Medicine · doi:10.1016/j.genm.2012.07.001 · Cited by 20
Ramos, J. E., Al‐Nakkash, L., Peterson, A., Gump, B. S., Janjulia, T., Moore, M. S., Broderick, T. L., & Carroll, C. C. (2012) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/j.1600-0838.2012.01516.x · Cited by 20
Efficacy, Safety, and Tolerability of Low-Dose Hormone Therapy in Managing Menopausal Symptoms
Langer, R. D. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.05.080134 · Cited by 20
Prakash, C., Johnson, K. A., & Gardner, M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020404 · Cited by 20
Self-citationEstrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60
Studd, J. W. W. (2009) · Climacteric · doi:10.1080/13697130902721873 · Cited by 20
Managing Hypertension in Patients with CKD
Chertow, G. M., Beddhu, S., Lewis, J. B., Toto, R. D., & Cheung, A. K. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015101125 · Cited by 20
Adeyanju, O. A., Soetan, O. A., Soladoye, A. O., & Olatunji, L. A. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2017-0630 · Cited by 20
Fan, X., he, S. T., Song, H., Yin, W., Zhang, J., Peng, Z., Yang, K., Zhai, X., Zhao, L., Gong, H., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02423-5 · Cited by 20
Ménopause et risque cardiovasculaire
Dessapt, A. L., & Gourdy, P. (2012) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2012.09.003 · Cited by 24
A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD)
Deligiannidis, K. M., Rothschild, A. J., BARTON, B. A., Kroll‐Desrosiers, A., Meyers, B. S., Flint, A. J., Whyte, E. M., Mulsant, B. H., & STOP-PD Study Group (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08400 · Cited by 20
Bensaleh, H., Belgnaoui, F., Douira, L., Berbiche, L., Senouci, K., & Hassam, B. (2006) · Annales d Endocrinologie · doi:10.1016/s0003-4266(06)73009-8 · Cited by 20
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Corson, S. L. (2009) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2009.02.003 · Cited by 20
Clinical Pharmacology and Therapeutics of Antidepressants
Ciraulo, D. A., Tsirulnik-Barts, L., Shader, R. I., & Greenblatt, D. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-792-5_2 · Cited by 20
Estrogen Receptor Beta Does Not Influence Ischemic Tolerance in the Aged Female Rat Heart
Tomicek, N. J., Miller‐Lee, J. L., Hunter, J. C., & Korzick, D. H. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00288.x · Cited by 20
Suter, E., Verhoef, M. J., Bockmuehl, C., Forest, N., Bobey, M., & Armitage, G. D. (2007) · PubMed Central · Cited by 20
Informing women about hormone replacement therapy: the consensus conference statement
Consensus Conference Working Group, Mosconi, P., Donati, S., Colombo, C., Mele, A., Liberati, A., & Satolli, R. (2009) · BMC Women s Health · doi:10.1186/1472-6874-9-14 · Cited by 21
Menopause and its Cardiometabolic Consequences: Current Perspectives
Anagnostis, P. G., & Goulis, D. G. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117999190228123237 · Cited by 19
Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis
Bontempo, S., Yeganeh, L., Giri, R., & Vincent, A. J. (2023) · Climacteric · doi:10.1080/13697137.2023.2273524 · Cited by 19
Sex differences in patients presenting with acute coronary syndrome: a state-of-the-art review
Zilio, F., Musella, F., Ceriello, L., Ciliberti, G., Pavan, D., Manes, M. T., Selimi, A., Scicchitano, P., Iannopollo, G., Albani, S., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102486 · Cited by 20
The impact of female sex hormones on cardiovascular disease: from mechanisms to hormone therapy
Kan, Y., Peng, Y., Zhao, Z.-H., Dong, S., Xu, Y.-X., Ma, X., Liu, X., Liu, Y., & Yu-Jie, Z. H. O. U. (2024) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2024.06.003 · Cited by 25
Al‐Nakkash, L., Markus, B., Batia, L. M., Prozialeck, W. C., & Broderick, T. L. (2010) · Journal of Medicinal Food · doi:10.1089/jmf.2009.0271 · Cited by 19
New Insights into Sexual Dimorphism during Progression of Heart Failure and Rhythm Disorders
Thireau, J., Aimond, F., Poisson, D., Zhang, B., Bruneval, P., Eder, V., Richard, S., & Babuty, D. (2010) · Endocrinology · doi:10.1210/en.2009-1184 · Cited by 19
What if the Women’s Health Initiative had used transdermal estradiol and oral progesterone instead?
Simon, J. A. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000169 · Cited by 19
Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow
Fernandes, C. E., Pompei, L. D. M., Machado, R. B., Ferreira, J. A. D. S., de Melo, N. R., & Peixoto, S. V. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.02.001 · Cited by 19
Williams, M. S., Cushman, M., Ouyang, P., Heckbert, S. R., Kalyani, R. R., & Vaidya, D. M. (2015) · Journal of Women s Health · doi:10.1089/jwh.2015.5465 · Cited by 19
Self-citationRen, Q., Yu, X., Liao, F., Chen, X., Yan, D., Nie, H., Fang, J., Yang, M., & Zhou, X. (2018) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2018.03.012 · Cited by 19
Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ
Wadsten, C., Wennstig, A.-K., Garmo, H., Nilsson, G., BLOMQVIST, C. P., Holmberg, L., Fredriksson, I., Wärnberg, F., & Sund, M. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4803-1 · Cited by 19
van Breemen, R. B., Chen, L., Tonsing‐Carter, A., Banuvar, S., Barengolts, E. I., Viana, M. A. G., Chen, S., Pauli, G. F., & Bolton, J. L. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c01077 · Cited by 19
Peterson, H. B., Thacker, S. B., Corso, P. S., Marchbanks, P. A., & Koplan, J. P. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.21.2308 · Cited by 19
Metadata
- Authors
- Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., Strickland, O. L., Wong, N. D., Crouse, J. R., Stein, E., & Cushman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- George Washington University (US)
- University of Tennessee Health Science Center (US)
- National Heart, Lung, and Blood Institute (US)
- Memorial Hospital of Rhode Island (US)
- Rutgers New Jersey Medical School (US)
- University at Buffalo, State University of New York (US)
- Rush University Medical Center (US)
- University of Washington (US)
- University of California, Los Angeles (US)
- Emory University (US)
- University of California, Irvine (US)
- Wake Forest University (US)
- University of Vermont (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-08-07
- Volume
- 349
- Issue
- 6
- Pages
- 523-534
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981922048
- Cited by
- 2,065
- References
- 35
- Citations by year
- 2026: 32 · 2025: 43 · 2024: 34 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 51 · 2019: 48 · 2018: 51 · 2017: 59 · 2016: 42 · 2015: 67 · 2014: 73 · 2013: 109 · 2012: 99
- FWCI
- 123.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- estrogen plus progestin, coronary artery disease, hormone replacement therapy, Women's Health Initiative, postmenopausal women, conjugated equine estrogens, medroxyprogesterone acetate, myocardial infarction, cardiovascular risk, LDL cholesterol, C-reactive protein, trial termination
- MeSH terms
- Aged, Coronary Disease, Double-Blind Method, Drug Combinations, Estrogens, Conjugated (USP), Female, Follow-Up Studies, Heart Diseases, Humans, Middle Aged, Myocardial Infarction, Risk Factors, Proportional Hazards Models, Case-Control Studies, Treatment Outcome, Medroxyprogesterone Acetate, Postmenopause, Hormone Replacement Therapy, Progesterone Congeners
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
